Gary S. Gillheeney Sells 18,416 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney sold 18,416 shares of the firm’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $3.65, for a total transaction of $67,218.40. Following the completion of the transaction, the chief executive officer now directly owns 3,400,778 shares of the company’s stock, valued at approximately $12,412,839.70. This trade represents a 0.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Organogenesis Stock Up 5.1 %

Organogenesis stock opened at $3.68 on Wednesday. The company has a market cap of $487.89 million, a P/E ratio of -61.33 and a beta of 1.73. Organogenesis Holdings Inc. has a 1-year low of $2.16 and a 1-year high of $4.70. The company has a fifty day simple moving average of $3.39 and a 200 day simple moving average of $2.98. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21.

Organogenesis (NASDAQ:ORGO) last released its earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.11. The business had revenue of $115.18 million during the quarter, compared to the consensus estimate of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same quarter last year, the firm earned $0.02 earnings per share. Research analysts anticipate that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ORGO. Price T Rowe Associates Inc. MD grew its position in shares of Organogenesis by 11.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 50,951 shares of the company’s stock valued at $145,000 after acquiring an additional 5,359 shares during the period. CWM LLC grew its position in shares of Organogenesis by 301.8% in the 2nd quarter. CWM LLC now owns 25,617 shares of the company’s stock valued at $72,000 after acquiring an additional 19,242 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Organogenesis by 309.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company’s stock valued at $11,136,000 after acquiring an additional 3,005,450 shares during the period. Pallas Capital Advisors LLC bought a new position in shares of Organogenesis in the 2nd quarter valued at about $38,000. Finally, Bank of New York Mellon Corp grew its position in shares of Organogenesis by 9.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 393,798 shares of the company’s stock valued at $1,103,000 after acquiring an additional 33,990 shares during the period. Institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.